Try our beta test site
18 studies found for:    algenpantucel-L
Show Display Options
Rank Status Study
1 Terminated Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable
Interventions: Drug: mFOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: SBRT;   Drug: Gemcitabine
2 Active, not recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
3 Completed Immunotherapy Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
4 Completed The Effect of a Behavioural Intervention on Injury Prevention Program Adherence in Female Youth Soccer
Condition: Sport Injury
Interventions: Behavioral: HAPA-based coach education workshop;   Behavioral: placebo attention control
5 Completed Vaccine Treatment for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
6 Completed Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
7 Terminated Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
8 Enrolling by invitation The Effect of Theory Menu-Based Intervention on Vitamin D Adherence in People With Osteoporosis-Pilot Study
Condition: Osteoporosis
Interventions: Behavioral: HAPA menu-based mini-video;   Behavioral: Standard care
9 Completed Increasing Vitamin Intake and Physical Activity
Conditions: Heart Diseases;   Diabetes Mellitus, Type 2;   Behavior;   Motivation
Intervention: Behavioral: Intervention Group (IG)
10 Unknown  The Possible Influence of Health Promotion Coaching on Health Related and Organizational Outcomes Among Nurses
Condition: Healthy
Intervention: Behavioral: Health Coaching
11 Completed Promoting Smoking Cessation in the Community Via QTW 2014
Condition: Smoking Cessation Intervention
Intervention: Behavioral: Quit immediately (QI) / cut down to quit (CDTQ)
12 Completed Enhancing Family Well-being Project
Condition: Family Relationship, Family Health, Happiness and Harmony
Intervention: Other: A theory-based action planning toolkit
13 Completed Intra-oral Camera in Gingival Health
Conditions: Gingival Hemorrhage;   Gingivitis;   Health Behavior;   Communication
Interventions: Behavioral: SPT consultation;   Device: SOPROCARE®
14 Completed Promoting Smoking Cessation in the Community Via Quit to Win Contest 2013
Condition: Smoking Cessation
Interventions: Behavioral: Informed early monetary incentive;   Behavioral: Uninformed early monetary incentive
15 Completed A Physical Activity Intervention for Female Shift Workers
Condition: Physical Activity
Intervention: Behavioral: Exercise
16 Recruiting Short-bout Handgrip Exercise for Smoking Cessation
Condition: Smoking Cessation
Interventions: Behavioral: Video about exercise;   Behavioral: App about exercise;   Behavioral: Leaflet about exercise;   Behavioral: Video about diet;   Behavioral: App about diet;   Behavioral: Leaflet about diet
17 Completed Behavioral Exercise Therapy and Multidisciplinary Rehabilitation for Chronic Non-specific Low Back Pain
Condition: Chronic Low Back Pain
Interventions: Behavioral: Behavioral Medical Rehabilitation plus behavioral exercise therapy;   Behavioral: Usual Behavioral Medical Rehabilitation
18 Completed Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Conditions: Rectal Cancer;   Colon Cancer
Interventions: Drug: FOLFOX-4;   Drug: AMG 706;   Biological: Panitumumab (Part 1a only);   Drug: FOLFIRI

Study has passed its completion date and status has not been verified in more than two years.